These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22080337)

  • 1. Identifying specific chemotherapeutic agents in Medicare data: a validation study.
    Lund JL; Stürmer T; Harlan LC; Sanoff HK; Sandler RS; Brookhart MA; Warren JL
    Med Care; 2013 May; 51(5):e27-34. PubMed ID: 22080337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the SEER-Medicare data to identify chemotherapy use.
    Warren JL; Harlan LC; Fahey A; Virnig BA; Freeman JL; Klabunde CN; Cooper GS; Knopf KB
    Med Care; 2002 Aug; 40(8 Suppl):IV-55-61. PubMed ID: 12187169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construct validity of medicare chemotherapy claims: the case of 5FU.
    Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA
    Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of SEER Treatment Data With Medicare Claims.
    Noone AM; Lund JL; Mariotto A; Cronin K; McNeel T; Deapen D; Warren JL
    Med Care; 2016 Sep; 54(9):e55-64. PubMed ID: 24638121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.
    Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL
    Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of electronic data on chemotherapy and hormone therapy use in HMOs.
    Ritzwoller DP; Carroll N; Delate T; O'Keeffe-Rossetti M; Fishman PA; Loggers ET; Aiello Bowles EJ; Elston-Lafata J; Hornbrook MC
    Med Care; 2013 Oct; 51(10):e67-73. PubMed ID: 22531648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
    Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
    J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study.
    Fleming ST; Kimmick GG; Sabatino SA; Cress RD; Wu XC; Trentham-Dietz A; Huang B; Hwang W; Liff JM;
    Ann Epidemiol; 2012 Nov; 22(11):807-13. PubMed ID: 22948184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.
    Gold HT; Do HT
    Health Serv Res; 2007 Oct; 42(5):2056-69. PubMed ID: 17850533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.
    Lamont EB; Lan L
    Med Care; 2014 Mar; 52(3):e15-20. PubMed ID: 22410411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provider Differences in Use of Implanted Ports in Older Adults With Cancer.
    Lipitz-Snyderman A; Elkin EB; Atoria CL; Sima CS; Epstein AS; Blinder V; Sepkowitz KA; Bach PB
    Med Care; 2015 Jul; 53(7):646-52. PubMed ID: 26035043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans.
    Whittle J; Steinberg EP; Anderson GF; Herbert R
    Med Care; 1991 Dec; 29(12):1226-36. PubMed ID: 1745080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement.
    Baldwin LM; Adamache W; Klabunde CN; Kenward K; Dahlman C; L Warren J
    Med Care; 2002 Aug; 40(8 Suppl):IV-82-95. PubMed ID: 12187173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diffusion of docetaxel in patients with metastatic prostate cancer.
    Unger JM; Hershman DL; Martin D; Etzioni RB; Barlow WE; LeBlanc M; Ramsey SR
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25540245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
    Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
    [No Abstract]   [Full Text] [Related]  

  • 17. The utility of Medicare claims data for measuring cancer stage.
    Cooper GS; Yuan Z; Stange KC; Amini SB; Dennis LK; Rimm AA
    Med Care; 1999 Jul; 37(7):706-11. PubMed ID: 10424641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment.
    Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA
    Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data.
    Huepenbecker SP; Zhao H; Sun CC; Fu S; He W; Giordano SH; Meyer LA
    JCO Clin Cancer Inform; 2022 Mar; 6():e2100187. PubMed ID: 35297648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data.
    Du X; Goodwin JS
    J Clin Oncol; 2001 Mar; 19(5):1455-61. PubMed ID: 11230491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.